Total trials
98
Active
20
Phase 3
5
Total enrollment
46,796
Pipeline matrix
Showing 13 of 13 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Psychopharmacological treatment | — | — | — | — | — | 1 | |
| Blinatumomab | — | — | — | — | — | 4 | |
| Imatinib | — | — | — | — | 2 | ||
| Chemotherapy | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Ponatinib | — | — | — | — | — | 1 | |
| Osimertinib | — | — | — | — | — | 1 | |
| Pemetrexed | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| Isatuximab | — | — | — | — | — | 1 | |
| Psychiatric medication kept constant over study duration | — | — | — | — | — | 1 |
Next readouts
- 2025-11
- 2026-04-30
- 2026-12-31
- 2028-01
- 2028-02
- 2029-01-01
- 2029-07-01
Top conditions
- Adult Acute Lymphocytic Leukemia7
- Acute Lymphoblastic Leukemia3
- Depression2
- Anxiety Disorder2
- Sepsis2
- Humerus Fracture Displaced Proximal2
- Mental Disorders2
- Platelet Function2
Frequently asked questions about Goethe University
- How many clinical trials does Goethe University have on ClinicalTrials.gov?
- Goethe University is listed as the lead sponsor on 98 clinical trials in ClinicalTrials.gov, 20 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Goethe University's trials are in Phase 3?
- 5 of Goethe University's trials are in Phase 3, spread across 13 active drug programs.
- What therapeutic areas does Goethe University focus on?
- Goethe University's most-studied conditions on ClinicalTrials.gov are Adult Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Depression, Anxiety Disorder, Sepsis.
- When are Goethe University's next clinical trial readouts?
- Goethe University has 7 upcoming primary-completion readouts tracked here; the soonest is “Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)”, expected around 2025-11.